for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adamis Pharmaceuticals Corp

ADMP.OQ

Latest Trade

0.55USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.48

 - 

3.28

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.55
Open
--
Volume
--
3M AVG Volume
17.55
Today's High
--
Today's Low
--
52 Week High
3.28
52 Week Low
0.48
Shares Out (MIL)
61.44
Market Cap (MIL)
34.03
Forward P/E
-1.06
Dividend (Yield %)
--

Next Event

Q3 2019 Adamis Pharmaceuticals Corp Earnings Release

Latest Developments

More

Adamis Pharmaceuticals Announces Commercial Partnership With Emerge Health For Symjepi In Australia And New Zealand

Adamis Pharma Corp - Co Strengthens Patent Portfolio For Its U.S. Compounding Subsidiary

Adamis Pharmaceuticals Says Qtrly Revenues About $5.8 Mln, Grew 17.5% Over Q1

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Industry

Biotechnology & Drugs

Contact Info

11682 El Camino Real Ste 300

+1.858.9972400

http://www.adamispharmaceuticals.com/

Executive Leadership

Richard C. Williams

Consultant, Director, Independent Chairman of the Board

Dennis J. Carlo

President, Chief Executive Officer, Director

Robert O. Hopkins

Chief Financial Officer, Vice President - Finance

David J. Marguglio

Senior Vice President, Chief Business Officer and Director

Karen K. Daniels

Vice President - Operations

Key Stats

2.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.450

2017

-0.900

2018

-1.000

2019(E)

-0.523
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.82
Price To Book (MRQ)
0.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.01
LT Debt To Equity (MRQ)
0.01
Return on Investment (TTM)
-120.01
Return on Equity (TTM)
-88.63

Latest News

Latest News

Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen.

BRIEF-Adamis Pharmaceuticals’ Commercial Partner Launches Symjepi (Epinephrine) In The US

* ADAMIS’ COMMERCIAL PARTNER LAUNCHES SYMJEPI™ (EPINEPHRINE) IN THE US

Novartis to launch Adamis' EpiPen rival in U.S. next year

Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

BRIEF-Adamis Pharmaceuticals Provides Update On Symjepi's U.S. Launch

* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON THE U.S. LAUNCH OF SYMJEPI

BRIEF-Adamis Pharmaceuticals Says Working With Sandoz To Prepare Symjepi Launch

* ADAMIS PHARMACEUTICALS - WORKING CLOSELY WITH SANDOZ TO PREPARE A SUCCESSFUL LAUNCH FOR SYMJEPI

BRIEF-Adamis Pharmaceuticals Updates Symjepi Commercialization Plans

* ADAMIS PHARMACEUTICALS UPDATES SYMJEPI COMMERCIALIZATION PLANS

BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The  Supplemental New Drug Application

* ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE

BRIEF-Adamis Pharmaceuticals Subsidiary Develops Compound To Manage Ulcers In Horses

* US COMPOUNDING, A SUBSIDIARY OF ADAMIS PHARMACEUTICALS, DEVELOPS A UNIQUE COMPOUND TO MANAGE ULCERS IN HORSES Source text for Eikon: Further company coverage:

BRIEF-Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA

* ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi

* ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI

Adamis wins U.S. approval to sell EpiPen rival, shares soar

Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.

Adamis gets U.S. approval to sell EpiPen rival, shares soar

Adamis Pharmaceuticals on Thursday said it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that would compete with Mylan's widely used EpiPen, sending its shares up 50 percent.

BRIEF-Adamis Pharmaceuticals gets FDA approval for co's epinephrine pre-filled syringe

* Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe

BRIEF-Adamis Pharmaceuticals announces closing of public offering

* Adamis Pharmaceuticals announces closing of public offering of common stock and exercise of over-allotment option in full Source text for Eikon: Further company coverage:

BRIEF-Perceptive Advisors reports 5.57 pct stake in Adamis Pharma

* Perceptive Advisors LLC reports 5.57 percent passive stake in Adamis Pharmaceuticals Corp as of April 21 - SEC filing Source text: (http://bit.ly/2p9rcOW) Further company coverage:

BRIEF-Adamis Pharmaceuticals announces pricing of public offering of common stock

* Adamis Pharmaceuticals announces pricing of public offering of common stock

BRIEF-Adamis Pharmaceuticals announces proposed public offering of common stock

* Adamis Pharmaceuticals announces proposed public offering of common stock

BRIEF-Adamis Pharmaceuticals announces FDA acceptance of its Epinephrine Pre-filled Syringe

* Adamis Pharmaceuticals announces FDA acceptance of resubmission of its Epinephrine pre-filled syringe NDA Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up